KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Cash & Equivalents (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Cash & Equivalents for 15 consecutive years, with $128.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 85.27% to $128.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $128.4 million, a 85.27% increase, with the full-year FY2025 number at $128.4 million, up 85.27% from a year prior.
  • Cash & Equivalents was $128.4 million for Q4 2025 at Supernus Pharmaceuticals, down from $151.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $255.6 million in Q1 2021 to a low of $24.7 million in Q2 2023.
  • A 5-year average of $120.1 million and a median of $113.6 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: tumbled 85.75% in 2023, then surged 377.92% in 2025.
  • Supernus Pharmaceuticals' Cash & Equivalents stood at $203.4 million in 2021, then plummeted by 54.23% to $93.1 million in 2022, then decreased by 19.4% to $75.1 million in 2023, then decreased by 7.63% to $69.3 million in 2024, then surged by 85.27% to $128.4 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Cash & Equivalents are $128.4 million (Q4 2025), $151.4 million (Q3 2025), and $144.7 million (Q2 2025).